The big revamp at GlaxoSmithKline R&D includes a new collaboration on AI
A few weeks ago, when GlaxoSmithKline said it had recruited Pfizer vet Tony Wood to run the platform tech and science group in the pharma R&D operation, the company noted that he was taking the place of John Baldoni, a senior research exec who was launching a new effort to use artificial intelligence technology to ramp up a new approach to drug identification and development.
This morning, we learned that Baldoni has decided to team with Insilico Medicine out of Baltimore, which also recently scored a joint venture with an upstart anti-aging biotech — Juvenescence — being launched by UK billionaire Jim Mellon and some high-profile biotech colleagues he’s been working with. The deal comes just a few weeks after Baldoni struck a pact with Exscientia, another AI company based in the UK.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.